Page	1	$of^3$	١

•					
N	<b>Mark</b>	ed-U	Jp V	Versi	or

Form PTO-1449 U.S. Department of Cathone (REV. 2-82) Patent and Transfer Office

Atty. Docket No. AP32738 066876.0103 Serial No. 09/955,877

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Said I.A. SHALABY et al.

Filing Date September 19, 2001 Group 1654

**U.S. PATENT DOCUMENTS** 

*Exam. Init.	Document No.							Date Name	Class	Class Subclass		
	5	8	7	6	7	2	8	03/02/1999	Kass HD et al.			
	5	8	7	4	8	0	4	02/23/1999	Rogers SP			
	5	6	4	8	0	8	9	07/15/1997	Shawkat T			
		<u> </u>	<u> </u>	l	<u></u>		l	FOREIGN PA	TENT DOCUMENT		L	1

	Document No.							Date	Country	Class	SubClass	Trans Yes	
		7	9	3	9	6	4	09/10/1999	Europe (EP)				

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	Harvard School of Public Health Jan 2004, <a href="http://www.researchmatters.harvard.edu/story.php?article_id=673">http://www.researchmatters.harvard.edu/story.php?article_id=673</a>
	Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;
	Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS, Wall Street Journal December 8, 2003 <a href="http://online.wsj.com/article/0">http://online.wsj.com/article/0</a> ,SB107083909136415400-email,00.html>
	Abramowicz M, ed., "Enfuvirtide (Fuzeon) for HIV Infection" Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;
	El-Awady, et al., Chem. Clinical Clinica Chimica Acta, 283(1-2):1-14 (1999);
	McHutchison et al., "Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment fro Chronic Hepatitis C", New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;

NY02:472768.1

Examiner

Date Considered

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

6 2004 L	
6 2004 []	Page 2 of 3

Form PTO-14	49 U.S. Department of Control	nerce
(REV. 2-82)	Patent and mademarks ffic	:e

Marked-Up Version

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
AP32738 066876.0103	09/955,877
Applicant Said I.A. SHALABY et al.	

	(Use several sheets if necessary)	September 19, 2001	1654
	YokozbawaYokozawa, et al., J. Traditional M	1edicine. 15(4):202-20715(1):45-5	1 (1998)
	TOROZOUWA <u>TOROZUWA</u> , et ali, et Tudaliolari		_ ()
	Alter, M.J., Hepatology, 26(1):625-65562S-6	<u>5S</u> (1997)	
•	Alam, et al., Phytotherapy Research, 10(1):58	3-61 (1996);	
	D.S. Chen, J. Formos. Med. Assoc., 95(1):6-1	2 (1996);	
	Detre, et al., Viral Hepatitis Rev., 2:219-228	(1996);	
	D.C. Dale and D.D. Federman, eds., Sci. Ame	er. Medicine- <del>Sc. Amer., Inc.</del> , Nev	v York, 4(8):1 <del>-8 (1995<u>10 (1996</u>);</del>
	HippsHibbs, et al., J. Infect. Dis. 168:789-790	0 (1993);	
	Lok, et al., Gastroenterology, 105(6):1833-18	38 (1993);	
	FieldsFlint SJ et al., Principles of Virology: N Press, ASM Press, Washington DC, 1990-p69		and Control2nd ed, New York, Raven
	Medicinal Plants of North Africa, Loutfy Box	ilos, Reference Publications, Inc.	, pp.150-51 (1983);
****	Medicinal Plants of North Africa, pp. 74-75.	<u>92-93</u> (1983);	
	Bergmeyer and Horder, Clin. Chen. Clinica C	hemica Acta <del>105147 f.</del> 105:147f-	<u>154f</u> (1980);
	Encyclopedia of Common Natural Ingredient p.169 (1980);	s, Used in Food, Drugs, and Cost	netics, John Wiley & Sons, New York,
.=	International Federation of Clinical Chemistr (1980);	y, Scientific Committee, J. Clin.	Chem. Clin. Biochem., 18:521-534

NY02:472768.1

Examiner Date Considered

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

	OIPEVOI				
Marked-Up Version	MAY 2 6 2004 5	Page 3 o			
Form PTO-1449 U.S. De (REV. 2-82) Patent an	epartment of Commerce d Tradesage Commerce	Atty. Docket No. AP32738 066876.0103	Serial No. 09/955,877		
	DISCLOSURE STATEMENT APPLICANT	Applicant Said I.A. SHALABY et al.			
	ral sheets if necessary)	Filing Date September 19, 2001	Group 1654		
Berg	meyer H. U. Principles Methods of Enzyn	natic Analysis. Verlag Chemic, (19	978) <u>, pp. 130-135;</u>		
Babb	oar, et al., Ind. J. Exp. Biol., 8:304-312 (19	970);			
Linu	s Pauling, General Chemistry, New York,	, Raven Press Dover Publications,	Inc., 1970, p 744.		
	·				
<u> </u>					
			·		
NY02:472768.1		•			
Examiner	Date	e Considered			

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.